Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pep-Therapy and Institut Curie Granted Approval from Ansm to Start First-in-Human Clinical Trial of Pep-010 for Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Italian Angels for Growth","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"Undisclosed","newsHeadline":"PEP-Therapy Raises \u20ac2.75 Million in Series A Financing to Advance Its Lead Candidate, PEP-010, Into the Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Anaxago","pharmaFlowCategory":"D","amount":"$6.4 million","upfrontCash":"Undisclosed","newsHeadline":"PEP-Therapy Extends Series-A Financing, Raising a Total of \u20ac5.4 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for The Treatment of Advanced Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by PEP-Therapy

    Menu

    PEP-Therapy

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PEP-Therapy

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for The Treatment of Advanced Solid Tumors

              Details:

              PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology for the treatment of advanced solid tumors.

              Lead Product(s): PEP-010

              Therapeutic Area: Oncology Product Name: PEP-010

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PEP-Therapy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PEP-Therapy Extends Series-A Financing, Raising a Total of €5.4 Million

              Details:

              PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy's innovative Cell Penetrating & Interfering Peptide (CP&IP) technology.

              Lead Product(s): PEP-010

              Therapeutic Area: Oncology Product Name: PEP-010

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Anaxago

              Deal Size: $6.4 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing July 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PEP-Therapy

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PEP-Therapy Raises €2.75 Million in Series A Financing to Advance Its Lead Candidate, PEP-010, Into the Clinic

              Details:

              PEP-Therapy will use the funds to progress the clinical development of PEP-010, PEP-Therapy's lead Cell Penetrating & Interfering Peptide (CP&IP), for the treatment of advanced solid tumors.

              Lead Product(s): PEP-010

              Therapeutic Area: Oncology Product Name: PEP-010

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Italian Angels for Growth

              Deal Size: $3.5 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing April 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PEP-Therapy

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pep-Therapy and Institut Curie Granted Approval from Ansm to Start First-in-Human Clinical Trial of Pep-010 for Advanced Solid Tumors

              Details:

              PEP-010 is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.

              Lead Product(s): PEP-010

              Therapeutic Area: Oncology Product Name: PEP-010

              Highest Development Status: Phase I Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY